Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ARIAD Pharmaceuticals Inc (NASDAQ:ARIA)

8.20
Delayed Data
As of Jul 25
 +0.09 / +1.11%
Today’s Change
4.37
Today|||52-Week Range
10.07
+31.20%
Year-to-Date
Cancer Stocks: 2 to Buy, 1 to Avoid
Jul 23 / MotleyFool.com - Paid Partner Content
Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)
Jul 20 / TheStreet.com - Paid Partner Content
Ariad Pharmaceuticals (ARIA) In Focus: Stock Jumps 8.2%
Jul 21 / Zacks.com - Paid Partner Content
Is Agenus or Ariad Pharmaceuticals the Better Long-Term Buy?
Jul 19 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close8.11
Today’s open8.07
Day’s range7.98 - 8.24
Volume5,554,455
Average volume (3 months)4,190,472
Market cap$1.6B
Dividend yield--
Data as of 07/25/2016

Growth & Valuation

Earnings growth (last year)-41.38%
Earnings growth (this year)+41.46%
Earnings growth (next 5 years)+41.39%
Revenue growth (last year)+12.70%
P/E ratioNM
Price/Sales9.93
Price/Book--

Competitors

 Today’s
change
Today’s
% change
RLYPRelypsa Inc-0.10-0.31%
AXONAxovant Sciences Ltd+0.25+1.77%
MCRBSeres Therapeutics I...-0.46-1.33%
FPRXFive Prime Therapeut...+0.54+1.14%
Data as of 07/25/2016

Financials

Next reporting dateAugust 3, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$118.8M
Annual profit (last year)-$231.2M
Net profit margin-194.57%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Paris Panayiotopoulos
Chief Financial Officer, Treasurer &
Executive VP
Manmeet Singh Soni
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs